What is it about?
This shows the therapeutic application of ZnONPs as a safe anti-diabetic agent and to have a potential for the control of diabetes.
Featured Image
Why is it important?
The possible hypoglycaemic and antioxidant effect of ZnONPs was explored. Upon treatment with ZnONPs, a significant alteration in the activities of superoxide dismutase, glutathione peroxidase, and the levels of insulin, haemoglobin A1c, and the expression of cluster of differentiation 4+ (CD4+), CD8+ T cells, glucose transporter type-4 (GLUT-4), tumour necrosis factor, and interleukin-6 when compared to diabetic and their control rats. ZnONPs' administration to the diabetic group showed eminent blood glucose control and restoration of the biochemical profile. This raises their active role in controlling pancreas functions to improve glycaemic status as well as the inflammatory responses.
Perspectives
This study evaluated the biochemical, molecular, and histopathological mechanisms involved in the hypoglycaemic effect of zinc oxide nanoparticles (ZnONPs) in experimental diabetic rats. ZnONPs were characterised by scanning and transmission electron microscopy (SEM and TEM).
Amr Negm
King Faisal University
Read the Original
This page is a summary of: Zinc oxide nanoparticles augment CD4, CD8, and GLUT-4 expression and restrict inflammation response in streptozotocin-induced diabetic rats, IET Nanobiotechnology, August 2020, the Institution of Engineering and Technology (the IET),
DOI: 10.1049/iet-nbt.2020.0079.
You can read the full text:
Contributors
The following have contributed to this page
